Capivasertib-fulvestrant therapy increases PFS in HR-positive breast cancer
For patients with hormone receptor-positive advanced breast cancer with disease progression during or after treatment with an aromatase inhibitor, capivasertib-fulvestrant therapy results in significantly longer progression-free ...
Jun 5, 2023
0
0